Concepta PLC Directorate change (0805C)
27 September 2018 - 4:02PM
UK Regulatory
TIDMCPT
RNS Number : 0805C
Concepta PLC
27 September 2018
27 September 2018
Concepta PLC
("Concepta" or the "Company")
Directorate change
As set out in the Interim Results announcement issued earlier
today, the Company is pleased to announce the appointment of Dr
David Darrock, Chief Operating Officer, as a Director of the
Concepta plc board.
Dr Darrock's full name is David John Darrock, he is 40 years
old.
The following disclosures are made in line with the AIM Rules
for Companies:
Current directorships/partnerships: None
Directorships and partnerships held within the last five years:
None
Shareholding : Dr Darrock holds no shares in the Company; and
holds options over 1,000,000 shares at an exercise price of 5.95
pence per share.
Save for the information set out above, there are no further
disclosures to be made in accordance with Rule 17, Schedule 2(g) of
the AIM Rules for Companies in respect of the appointment of Dr
David Darrock.
Enquiries:
The Company
Matthew Walls, Chairman Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin / Mark Brady Tel: +44 (0)20 368 3550
Novum Securities
Colin Rowbury +44 (0) 20 7399 9400
Yellow Jersey PR Limited (Financial PR)
Georgia Colkin / Joe Burgess/Katie Bairsto Tel: +44 (0) 776 932
5254
About Concepta PLC:
Concepta PLC is an AIM-quoted pioneering UK healthcare company
that has developed a proprietary product, myLotus, targeted at the
personalised mobile health market with a primary focus on fertility
and unexplained infertility in women.
myLotus is currently the only consumer product which allows both
quantitative and qualitative home (self test) test measurement of a
woman's personal luteinizing hormone (LH) during ovulation and
human chorionic gonadotropin (hCG) hormone level during pregnancy,
facilitating higher conception rates and early diagnosis of
fertility issues. The proposition of myLotus is to help women
conceive naturally by identifying their window of fertility and
optimal time for conception.
The Company anticipates receiving CE-mark certification for
myLotus over the coming months and is preparing its B2C launch in
the UK and Europe. The Company has identified a significant global
market opportunity with revenue potential of the EU and Chinese
unexplained infertility market estimated to be worth c.GBP600m per
annum.
Concepta has also made progress in establishing relationships
with a number of distributors in China where myLotus has been given
cFDA approval. Concepta is initially targeting the traditional
route to market in China through Chinese hospitals and plans to add
the B2C route in the near future.
Unexplained infertility refers to women that have been unable to
conceive after 6 months of trying. This highly motivated target
group of consumers won't typically be offered medical intervention
until 12 months of unsuccessfully trying, with IVF not offered
until two years. Research indicates couples start to take positive
action ahead of this time and there is little medical support to
help them do so.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAUNOWRWKAKUAR
(END) Dow Jones Newswires
September 27, 2018 02:02 ET (06:02 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2024 to May 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From May 2023 to May 2024